Eckert & Ziegler Supports Development of DARPin Radiolabeled Cancer Therapies Using Actinium-225 and Lutetium-177

Eckert & Ziegler Supports Development of DARPin Radiolabeled Cancer Therapies Using Actinium-225 and Lutetium-177

(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, leveraging its advanced laboratory infrastructure in Berlin. DARPin molecules offer customizable protein structures and favorable pharmacokinetics, making them promising carriers for targeted radiotherapy. The collaboration strengthens Eckert & Ziegler’s position as a partner for radiopharmaceutical innovation while supporting Molecular Partners’ efforts to advance DARPin-based cancer therapies from development toward clinical and commercial applications.

(PRESS RELEASE) BERLIN, 27-Feb-2026 — /EuropaWire/ — Eckert & Ziegler SE has formed a partnership with Molecular Partners AG to support the development and future manufacturing of radiolabeled therapeutics based on Molecular Partners’ proprietary Designed Ankyrin Repeat Protein (DARPin) platform. The collaboration focuses on advancing Radio-DARPin therapies that combine targeted protein technology with radioactive isotopes for potential use in cancer treatment.

As part of the agreement, Eckert & Ziegler will provide a broad range of development services for Radio-DARPins incorporating the radioisotopes Actinium-225 and Lutetium-177. These isotopes are widely regarded as promising components in targeted radiopharmaceutical therapies. The work will be carried out using Eckert & Ziegler’s specialized development infrastructure, including its recently established laboratory facility in Berlin. The laboratory is equipped with advanced technical systems specifically configured to support the development of radiopharmaceuticals, particularly those based on alpha-emitting isotopes.

DARPin molecules represent a novel category of engineered proteins designed with customizable structures and favorable pharmacokinetic characteristics. These properties make DARPin-based molecules suitable carriers for targeted radiopharmaceutical therapies aimed at treating cancers with significant unmet medical needs.

The partnership reflects Eckert & Ziegler’s strategy of supporting innovative radiopharmaceutical platforms from early-stage development through later manufacturing phases. By combining expertise in isotope production, radiochemistry, and development services with Molecular Partners’ DARPin technology, the collaboration aims to advance new therapeutic approaches for cancer patients.

Dr. Harald Hasselmann, Chief Executive Officer of Eckert & Ziegler, highlighted the importance of working with innovative biotechnology partners to advance promising treatment technologies. The collaboration is expected to strengthen Eckert & Ziegler’s role as a development and manufacturing partner within the expanding radiopharmaceutical sector.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

About Molecular Partners AG
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

Media Contacts:

Eckert & Ziegler
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Molecular Partners
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

SOURCE: Eckert & Ziegler SE